KYTX
HealthcareKyverna Therapeutics, Inc.
$8.13
$-0.64 (-7.30%)
Jan 5, 2026
Price History (1Y)
Analysis
Kyverna Therapeutics, Inc. is a biotechnology company operating in the healthcare sector with a market capitalization of $484.60 million and approximately 129 employees. The company's financial health indicates significant losses, with net income totaling -$160,992,000 and EBITDA reaching -$170,456,992 over the trailing twelve months. Free cash flow is also negative at -$95,628,248. The balance sheet shows a substantial amount of cash on hand at $171.14 million, while debt remains relatively low at $5.02 million. Kyverna Therapeutics' valuation metrics reveal a negative forward P/E ratio of -2.27 and an EV/EBITDA ratio of -1.28, indicating a complex financial situation. The company's gross margin, operating margin, and profit margin are all 0%, suggesting significant operational costs or inefficiencies.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Kyverna Therapeutics, Inc.
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Visit website →Key Statistics
- Market Cap
- $484.60M
- P/E Ratio
- N/A
- 52-Week High
- $13.67
- 52-Week Low
- $1.78
- Avg Volume
- 1.50M
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 129